Clinical Impact of 123I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center

被引:12
|
作者
Graebner, Allison K. [1 ]
Tarsy, Daniel [1 ]
Shih, Ludy C. [1 ]
Vanderhorst, Veronique [1 ]
Kulkarni, Omesh [1 ]
Kaplan, Scott [1 ]
Simon, David K. [1 ]
机构
[1] Harvard Med Sch, Parkinsons Dis & Movement Disorders Ctr, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Room CLS 638, Boston, MA 02215 USA
关键词
Parkinson's disease; Parkinsonism; DaTscan; Neuroimaging; Biomarker; Nigrostriatal system; Neurodegeneration; DAT-SPECT; DIAGNOSIS; ACCURACY; DISEASE;
D O I
10.1159/000447561
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background/Aims: The clinical diagnosis of degenerative forms of parkinsonism is imperfect, with past studies reporting a high rate of misdiagnosis by neurologists and movement disorder specialists, particularly early in the disease course. 123 I-ioflupane SPECT (DaTscan) is a diagnostic neuro-imaging tool used to distinguish essential tremor from tremor due to degenerative parkinsonisms. The present study expands upon prior studies of the clinical impact of DaTscan imaging in movement disorder centers by assessing quantitative estimates of diagnostic certainty, the impact on subsequent clinical decisions, and the degree to which the asymmetry in the results corresponds to laterality by clinical history and examination. Methods: In a prospective, observational study of the impact of DaTscan imaging in a movement disorder center over the course of 18 months, 4 specialists completed a questionnaire at the time they ordered imaging and again within 1 month after imaging. Results: Twenty-seven patients underwent DaTscan imaging; the result was normal in 4 cases (14.8%), abnormal in 22 cases (81.4%), and equivocal in 1 case (3.7%). In all cases of a normal result, the post-scan-predicted chance of degenerative parkinsonism decreased compared to the pre-scan prediction (p < 0.05), and in all cases of abnormal scan, the postscan chance of degenerative parkinsonism increased or remained high (p < 0.0001). Clinical impacts were observed following imaging in a total of 24 patients (88.9%), including changes in medications for 18 patients and psychological impacts for 11 patients. Asymmetric clinical symptoms were corroborated based on the expected asymmetry of dopamine uptake deficits in 57.1% of the cases, were not present in 23.8%, and were opposite of expectations in 19.0% of the scans. Conclusion: DaTscan imaging results have an impact on physician's confidence in the diagnosis of parkinsonism and may also have a psychological impact on patients. DaTscan imaging may be a useful adjunct to clinical history and examination in selected patients. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:38 / 43
页数:6
相关论文
共 50 条
  • [41] Impact of CT based attenuation correction on quantitative assessment of DaTSCAN (123I-Ioflupane) imaging in diagnosis of extrapyramidal diseases
    Blenkiewicz, M.
    Gorska-Chrzastek, M.
    Siennicki, J.
    Gajos, A.
    Bogucki, A.
    Mochecka-Thoelke, A.
    Selmaj, K.
    Kusmierek, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S304 - S305
  • [42] 123I-Ioflupane SPECT Findings of Pantothenate Kinase-Associated Neurodegeneration
    Kang, Arnold
    Minoshima, Satoshi
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (09) : 849 - 851
  • [43] Quantitative measurement of striatal uptake in 123I-ioflupane SPECT/CT images
    DiFilippo, Frank
    Brunken, Richard
    Wu, Guiyun
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [44] Application of partial-volume correction in 123I-Ioflupane SPECT imaging
    Thomas, Benjamin
    Dickson, John
    Erlandsson, Kjell
    Ourselin, Sebastien
    Hutton, Brian
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [45] 99mTcHM-PAO and 123I-Ioflupane brain SPECT usefulness in cognitive and movement associated disorders
    Nuvoli, S.
    Nieddu, A.
    Paulus, K. S.
    Rubattu, E.
    Chessa, F.
    Spanu, A.
    Madeddu, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S332 - S332
  • [46] Striatal 123I-Ioflupane SPECT abnormality in sporadic Creutzfeldt–Jakob disease
    Claire Hinnell
    Muriel Buxton-Thomas
    Naomi Sibtain
    Michael Samuel
    Journal of Neurology, 2011, 258 : 948 - 950
  • [47] A biokinetic and dosimetric model for 123I-ioflupane
    Tavola, F.
    Veronese, I.
    Cantone, M.
    Sydoff, M.
    Leide-Svegborn, S.
    Mattsson, S.
    Uusijarvi-Lizana, H.
    Giussani, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S313 - S313
  • [48] Comparative studies of collimator performance in DaTscan (Ioflupane I-123) striatal SPECT
    Krol, Andrzej
    McGrath, Mary A.
    Carey, Brian T.
    Feiglin, David H.
    MEDICAL IMAGING 2013: BIOMEDICAL APPLICATIONS IN MOLECULAR, STRUCTURAL, AND FUNCTIONAL IMAGING, 2013, 8672
  • [49] 123I-Ioflupane brain scintigraphy (DaTScan®) to demonstrate loss of nigrostratal dopaminergic neurons principles and applications
    Rémy, P
    Malek, Z
    Itti, E
    REVUE NEUROLOGIQUE, 2003, 159 (10) : 942 - 946
  • [50] COMPARATIVE STUDY OF THE SUBSTANTIA NIGRA ECHOGENICITY AND 123I-IOFLUPANE SPECT IN PATIENTS WITH REM SLEEP BEHAVIOR DISORDER
    Maskova, J.
    Skoloudik, D.
    Dusek, P.
    Sonka, K.
    Losada, V. Ibarburu Lorenzo Y.
    Kemlink, D.
    Dusek, P.
    Kubinyi, J.
    Trnka, J.
    Krupicka, R.
    Ruzicka, E.
    SLEEP MEDICINE, 2017, 40 : E212 - E212